The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 17, 2021

Filed:

Nov. 17, 2017
Applicants:

University of Pittsburgh—of the Commonwealth System of Higher Education, Pittsburgh, PA (US);

National Research Council of Canada, Ottawa, CA;

Inventors:

Andrew Peterson Hinck, Pittsburgh, PA (US);

Traian Sulea, Ottawa, CA;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 14/495 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/495 (2013.01); A61K 38/00 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01); C07K 2319/31 (2013.01);
Abstract

Recombinant transforming growth factor (TGF)-β monomers modified to inhibit dimerization and block TGF-β signaling are described. The recombinant TGF-β monomers lack the ability to bind and recruit TGF-β type I receptor (TβRI), but retain the capacity to bind the high affinity TGF-β type II receptor (TβRII), and in some instances, include mutations that increase their affinity for TβRII. Nucleic acid molecules and vectors encoding the recombinant TGF-β monomers are also described. Isolated cells, such as T cells, can be re-programmed with a TGF-β monomer-encoding nucleic acid or vector to secrete the monomer. Use of the recombinant TGF-β monomers and/or cells producing the recombinant TGF-β monomers, to inhibit TGF-β signaling, such as to treat disorders associated with aberrant TGF-β signaling, are also described.


Find Patent Forward Citations

Loading…